Neumora Therapeutics, Inc.(NMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NMRA Neumora Therapeutics, Inc.

Market Closed 12-12 16:00:00 EST

2.09

+0.02

+0.97%

盘后2.07

-0.02-0.96%

19:55 EST

High2.12	Low1.97	Vol618.39K
Open2.08	D1 Closing2.07	Amplitude7.24%
Mkt Cap355.30M	Tradable Cap179.87M	Total Shares170.00M
T/O1.27M	T/O Rate0.72%	Tradable Shares86.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":2.09,"timestamp":1765573200000,"preClose":2.07,"halted":0,"volume":618387,"hourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.09,"latestTime":"19:55 EST","volume":848,"amount":1752.224,"timestamp":1765587358799},"delay":0,"floatShares":86062982,"shares":170000000,"eps":-1.463171,"marketStatus":"Market Closed","change":0.02,"latestTime":"12-12 16:00:00 EST","open":2.08,"high":2.1199,"low":1.97,"amount":1265270.509734,"amplitude":0.072415,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.463171,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":2.07,"preHourTrading":{"tag":"盘前","latestPrice":2.1343,"preClose":2.07,"latestTime":"08:00 EST","volume":21,"amount":44.228301599999995,"timestamp":1765544411657},"postHourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.09,"latestTime":"19:55 EST","volume":848,"amount":1752.224,"timestamp":1765587358799},"volumeRatio":1.0296421285667758,"impliedVol":0.4551,"impliedVolPercentile":0.112},"requestUrl":"/m/hq/s/NMRA","defaultTab":"news","newsList":[{"id":"2588177016","title":"Neumora Therapeutics Shares Rise After RBC Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2588177016","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588177016?lang=en_us&edition=fundamental","pubTime":"2025-12-02 03:56","pubTimestamp":1764618984,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics  shares were up 8% in recent Monday trading after RBC Capital Markets upgraded the company's stock to outperform from sector perform and raised its price target to $7 from $4.Trading volume stood at over 1.8 million, versus the daily average of about 1.5 million.Price: 2.42, Change: +0.18, Percent Change: +8.04","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMRA"],"gpt_icon":0},{"id":"2588777403","title":"Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588777403","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588777403?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:45","pubTimestamp":1764614700,"startTime":"0","endTime":"0","summary":"RBC upgrades Neumora, citing strong early NLRP3 obesity data and growing pipeline momentum ahead of key 2026 readouts.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/01/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/01/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/upgrades/25/12/49144348/analyst-sees-value-in-neumoras-expanding-obesity-and-metabolic-pipeline","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/upgrades/25/12/49144348/analyst-sees-value-in-neumoras-expanding-obesity-and-metabolic-pipeline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4007","VTYX","NMRA"],"gpt_icon":0},{"id":"2588724301","title":"Neumora Therapeutics Raised to Outperform From Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724301","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724301?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:43","pubTimestamp":1764589380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NMRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 06:43 ET (11:43 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA"],"gpt_icon":0},{"id":"2588211577","title":"Shares of Neumora Therapeutics up 8% Premarket After RBC Raises to Outperform From Sector Perform","url":"https://stock-news.laohu8.com/highlight/detail?id=2588211577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588211577?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:21","pubTimestamp":1764588101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70M8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2588211117","title":"RBC Upgrades Neumora Therapeutics to Outperform From Sector Perform, Raises Price Target to $7 From $4, Keeps Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2588211117","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588211117?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:20","pubTimestamp":1764588045,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NMRA) has an average rating of overweight and mean price target of $9.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMRA"],"gpt_icon":0},{"id":"2588726105","title":"Neumora Therapeutics Inc : RBC Raises to Outperform From Sector Perform; Raises Target Price to $7 From $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2588726105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588726105?lang=en_us&edition=fundamental","pubTime":"2025-12-01 18:24","pubTimestamp":1764584675,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70CS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2585012527","title":"Neumora Therapeutics Issues 2.85 Million Shares to K2 HealthVentures in Loan Conversion","url":"https://stock-news.laohu8.com/highlight/detail?id=2585012527","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585012527?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:06","pubTimestamp":1763759160,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc. has announced the issuance of 2,849,327 shares of common stock to K2 HealthVentures Equity Trust LLC. This transaction follows the receipt of a conversion notice from K2 HealthVentures, which elected to convert $2.5 million of the outstanding principal under a term loan into common stock at a conversion price of $0.8774 per share. The shares were issued as unregistered securities under the exemption provided by Section 4 of the Securities Act of 1933.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL4dnPkY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2583175315","title":"Neumora Therapeutics Officer Daljit Singh Aurora Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583175315","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583175315?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:39","pubTimestamp":1763069994,"startTime":"0","endTime":"0","summary":"Daljit Singh Aurora, an officer at Neumora Therapeutics Inc, has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL9FqCDR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Neumora Therapeutics Officer Daljit Singh Aurora Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2582817535","title":"H.C. Wainwright Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582817535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582817535?lang=en_us&edition=fundamental","pubTime":"2025-11-10 09:16","pubTimestamp":1762737383,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Neumora Therapeutics, Inc., with a price target of $18...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-neumora-therapeutics-inc-nmra-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-neumora-therapeutics-inc-nmra-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA"],"gpt_icon":0},{"id":"2581830795","title":"13D Filings -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2581830795","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581830795?lang=en_us&edition=fundamental","pubTime":"2025-11-08 08:26","pubTimestamp":1762561560,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Oct. 30 through Nov. 5, 2025. Source: VerityData. Garrett Motion  Oaktree Value Opportunity Fund reduced its stake in the vehicle-parts maker to 25,894,816 shares. Oaktree did so through the sale of 6,000,000 Garrett Motion shares in a block sale to BofA Securities for $16.25 per share on Oct. 27. Following the latest sales, Oaktree Value Opportunity Fund continues to own 13.3% of Garrett Motion's outstanding stock. Shares of Garrett Motion have gained roughly 96% in value in 2025.Rogers  Starboard Value lowered its stake in the engineered products company to 1,203,457 shares. Starboard Value did so through the sale of 473,045 Rogers shares from Oct. 24 through Oct. 31 at per share prices ranging","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4140","BK4148","GROY","SG9999001135.SGD","SG9999006266.SGD","SGCmain","SG9999008742.SGD","GTX","MPLT","IAU","BK6062","159934","SG9999000475.SGD","518880","DUST","BK6515","OACB.U","USDT.USD.HKCC","IE0031619046.USD","BK4007","GCmain","MGCmain","NSIT","NUGT","BK4017","GDX","SG9999004360.SGD","V03.SI","BK4124","IE00B66KJ199.SGD","SGUmain","IE00B7SZL793.SGD","USDT.USD.CC","ROG","SG9999001846.SGD","IE00B19Z4B17.USD"],"gpt_icon":1},{"id":"2581005225","title":"Analysts Are Neutral on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), ICU Medical (ICUI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581005225","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581005225?lang=en_us&edition=fundamental","pubTime":"2025-11-07 18:10","pubTimestamp":1762510246,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Neumora Therapeutics, Inc. (NMRA – Research Report), ICU Medical (ICUI – Research Report) and Lemaitr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-these-healthcare-stocks-neumora-therapeutics-inc-nmra-icu-medical-icui-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-these-healthcare-stocks-neumora-therapeutics-inc-nmra-icu-medical-icui-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","ICU","NMRA","ICUI","XLV"],"gpt_icon":0},{"id":"2581018826","title":"Neumora Therapeutics, Inc.: Promising Growth and Innovation with Key Developments in Alzheimer’s Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2581018826","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581018826?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:16","pubTimestamp":1762445760,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wainwright ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/neumora-therapeutics-inc-promising-growth-and-innovation-with-key-developments-in-alzheimers-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/neumora-therapeutics-inc-promising-growth-and-innovation-with-key-developments-in-alzheimers-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","BK4007","BK4581","XLV","LABU","BK4585","BK4588","XBI"],"gpt_icon":0},{"id":"2581018874","title":"Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Charles River Labs (CRL) and Neumora Therapeutics, Inc. (NMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581018874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581018874?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:10","pubTimestamp":1762445438,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on QuidelOrtho (QDEL – Research Report), Charles River Labs (CRL – R...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-quidelortho-qdel-charles-river-labs-crl-and-neumora-therapeutics-inc-nmra-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-quidelortho-qdel-charles-river-labs-crl-and-neumora-therapeutics-inc-nmra-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","LU0757428866.USD","HCSG","BK4137","BK4588","BK4082","CRL","LU0390134368.USD","BK4581","NMRA","QDEL","XBI","BK4121","BK4530","BK4007","IE00BFMHRM44.USD","LU0128526141.USD","XLV","BK4585","LU0029874061.USD","LU1815336091.USD","LABU"],"gpt_icon":0},{"id":"2581220067","title":"Neumora Therapeutics Unveils Pipeline Advancements Targeting Major Brain Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2581220067","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581220067?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:23","pubTimestamp":1762431839,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc. has released a corporate presentation outlining its progress in neuroscience drug development. The company highlighted a broad pipeline targeting major indications, including major depressive disorder, Alzheimer's disease agitation, schizophrenia, obesity, Parkinson's disease, and ALS. Key programs include Navacaprant, a KOR antagonist for major depressive disorder, currently progressing toward pivotal data readouts; NMRA-511, a V1aR antagonist for agitation in Alzheimer's disease; and two M4 modulators, NMRA-861 and NMRA-898, for schizophrenia. The pipeline also features NMRA-215, an NLRP3 inhibitor for obesity and Parkinson's disease, as well as additional candidates targeting Parkinson's disease and ALS. Several clinical milestones are expected over the next year as the company advances its portfolio. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intell","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL8dHqn4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2581067228","title":"Neumora Therapeutics Q3 EPS $(0.35) Misses $(0.33) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581067228","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581067228?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:22","pubTimestamp":1762431723,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 4.79 percent. This is a 22.22 percent increase over losses of $(0.45) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48682814/neumora-therapeutics-q3-eps-0-35-misses-0-33-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA"],"gpt_icon":0},{"id":"2581906774","title":"Neumora Therapeutics Inc - on-Track to Report Data From Phase 1B Study of Nmra-511 in Alzheimer's Disease Agitation Around Year End","url":"https://stock-news.laohu8.com/highlight/detail?id=2581906774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581906774?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA4RZKPF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2581067785","title":"Neumora Therapeutics Inc -  Expects Cash, Cash Equivalents & Marketable Securities as of Sept 30, 2025, Will Fund Operating Plan Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581067785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581067785?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430407,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA4RZKPF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2581060866","title":"Neumora Therapeutics Inc - Drawn Additional $40 Mln From Existing Venture Debt Facility With K2 Healthventures","url":"https://stock-news.laohu8.com/highlight/detail?id=2581060866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581060866?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430407,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA4RZKPF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2580297374","title":"Neumora Therapeutics to Join Stifel Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2580297374","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580297374?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:00","pubTimestamp":1762171242,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc will participate in the Stifel 2025 Healthcare Conference with a fireside chat on Wednesday, November 12, 2025, at 2:00 p.m. ET in New York, NY. The event will be webcast live on the company's website, with a replay available for 30 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL2q9TVk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","NMRA","BK4112","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","SF","IE00B64PRP62.GBP","BK4127","IE00BKPKM429.USD","BK4585","BK4007"],"gpt_icon":0},{"id":"2580412995","title":"Neumora Therapeutics Inc  expected to post a loss of 33 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580412995","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580412995?lang=en_us&edition=fundamental","pubTime":"2025-11-01 06:32","pubTimestamp":1761949924,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc  expected to post a loss of33cents a share - Earnings Preview Neumora Therapeutics Inc NMRA.OQ NMRA.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC2KE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neumoratx.com","stockEarnings":[{"period":"1week","weight":-0.0586},{"period":"1month","weight":-0.2692},{"period":"3month","weight":0.2901},{"period":"6month","weight":1.4748},{"period":"1year","weight":-0.8025},{"period":"ytd","weight":-0.8028}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.","exchange":"NASDAQ","name":"Neumora Therapeutics, Inc.","nameEN":"Neumora Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neumora Therapeutics, Inc.(NMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neumora Therapeutics, Inc.(NMRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neumora Therapeutics, Inc.,NMRA,Neumora Therapeutics, Inc.股票,Neumora Therapeutics, Inc.股票老虎,Neumora Therapeutics, Inc.股票老虎国际,Neumora Therapeutics, Inc.行情,Neumora Therapeutics, Inc.股票行情,Neumora Therapeutics, Inc.股价,Neumora Therapeutics, Inc.股市,Neumora Therapeutics, Inc.股票价格,Neumora Therapeutics, Inc.股票交易,Neumora Therapeutics, Inc.股票购买,Neumora Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neumora Therapeutics, Inc.(NMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neumora Therapeutics, Inc.(NMRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction